Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS

Redenbaugh, Vyanka; Chia, N.; Cacciaguerra, Laura; McCombe, Jennifer A.; Tillema, Jan‐Mendelt; Chen, John J.; Chiriboga, A. Sebastian López; Sechi, Elia; Hacohen, Yael; Pittock, Sean J; Flanagan, Eoin P.

doi:10.1177/13524585231166834

Cited by 7 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not find differences in acute MOGAD lesion dynamics between children and adults, and prior analyses of longer-term lesion evolution have shown similar rates of lesion resolution in pediatric and adult MOGAD, suggesting this is related to MOGAD disease biology rather than being age dependent. 10 - 12 A prior study showed new asymptomatic lesions in MOGAD were most commonly detected at the first follow-up MRI scan after an attack but rarely developed later in the disease course, differing from MS. 26 , 27 Our data suggest that these asymptomatic lesions may not develop between clinical attacks, but rather more likely arise within the prior attack but are not captured on the initial attack MRI due to radiologic lag.…”

Section: Discussionmentioning

confidence: 99%

Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody–Associated Disease

Cacciaguerra,

Abdel-Mannan,

Champsas

et al. 2024

Neurology

Self Cite

View full text Add to dashboard Cite

Background and Objectives Knowledge of the evolution of CNS demyelinating lesions within attacks could assist diagnosis. We evaluated intra-attack lesion dynamics in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) vs multiple sclerosis (MS) and aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Methods This retrospective observational multicenter study included consecutive patients from Mayo Clinic (USA) and Great Ormond Street Hospital for Children (UK). Inclusion criteria were as follows: (1) MOGAD, MS, or AQP4+NMOSD diagnosis; (2) availability of ≥2 brain MRIs (within 30 days of attack onset); and (3) brain involvement (i.e., ≥1 T2 lesion) on ≥1 brain MRI. The initial and subsequent brain MRIs within a single attack were evaluated for the following: new T2 lesions(s); resolved T2 lesion(s); both; or no change. This was compared between MOGAD, MS, and AQP4+NMOSD attacks. We used the Mann-Whitney U test and χ 2 /Fisher exact test for statistical analysis. Results Our cohort included 55 patients with MOGAD (median age, 14 years; interquartile range [IQR] 5–34; female sex, 29 [53%]) for a total of 58 attacks. The comparison groups included 38 patients with MS, and 19 with AQP4+NMOSD. In MOGAD, the initial brain MRI (median of 5 days from onset [IQR 3–9]) was normal in 6/58 (10%) attacks despite cerebral symptoms (i.e., radiologic lag). The commonest reason for repeat MRI was clinical worsening or no improvement (33/56 [59%] attacks with details available). When compared with the first MRI, the second intra-attack MRI (median of 8 days from initial scan [IQR 5–13]) showed the following: new T2 lesion(s) 27/58 (47%); stability 24/58 (41%); resolution of T2 lesion(s) 4/58 (7%); or both new and resolved T2 lesions 3/58 (5%). Findings were similar between children and adults. Steroid treatment was associated with resolution of ≥1 T2 lesion (6/28 [21%] vs 1/30 [3%], p = 0.048) and reduced the likelihood of new T2 lesions (9/28 vs 18/30, p = 0.03). Intra-attack MRI changes favored MOGAD (34/58 [59%]) over MS (10/38 [26%], p = 0.002) and AQP4+NMOSD (4/19 [21%], p = 0.007). Resolution of ≥1 T2 lesions was exclusive to MOGAD (7/58 [12%]). Discussion Radiologic lag is common within MOGAD attacks. Dynamic imaging with frequent appearance and occasional disappearance of lesions within a single attack suggest MOGAD diagnosis over MS and AQP4+NMOSD. These findings have implications for clinical practice, clinical trial attack adjudication, and understanding of MOGAD pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody–Associated Disease

Cacciaguerra,

Abdel-Mannan,

Champsas

et al. 2024

Neurology

Self Cite

View full text Add to dashboard Cite

show abstract

“…14 Only 5 patients (4 of whom were adults) fulfilled the MOGAD criteria (i.e., they were MOG-Ab positive and had at least 1 supporting feature) but had a diagnosis of MS (e.g., false positive). In cases with diagnostic uncertainty, other factors, such as repeat testing in both the serum and CSF, 15 testing with live CBA, oligoclonal bands (which are more common in MS, although they can be seen in 20% of patients with MOGAD 16,17 ), and lesion dynamics on MRI 18,19 could be assessed over time to discriminate the demyelinating etiology, before commencing disease-modifying therapies.…”

Section: Discussionmentioning

confidence: 99%

Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children

Varley,

Champsas,

Prossor

et al. 2024

Neurology

Self Cite

View full text Add to dashboard Cite

Background and ObjectivesTo test the performance of the 2023 myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) criteria in adults and children with inflammatory demyelinating conditions who were tested for MOG antibodies (Abs). MethodsThis was a retrospective study of patients tested for MOG-Abs from 2018 to 2022 in 2 specialist hospitals. The inclusion criteria comprised ≥1 attendance in an adult or pediatric demyelinating disease clinic and complete clinical and MRI records. The final clinical diagnosis of MOGAD, made by the treating neurologist, was taken as the benchmark against which the new criteria were tested. The international MOGAD diagnostic criteria were applied retrospectively; they stipulate at least 1 clinical or MRI supporting feature for MOGAD diagnosis in positive fixed MOG cellbased assay without a titer. The performance MOG-Ab testing alone for MOGAD diagnosis was also assessed and compared with that of MOGAD criteria using the McNemar test. ResultsOf the 1,879 patients tested for MOG-Abs, 539 (135 pediatric and 404 adults) met the inclusion criteria. A clinical diagnosis of MOGAD was made in 86/539 (16%) patients (37 adults, 49 children), with a median follow-up of 3.6 years. The MOGAD diagnostic criteria had sensitivity of 96.5% (adults 91.9%, children 100%), specificity of 98.9% (adults 98.8%, children 98.9%), positive predictive value of 94.3% (adults 89.4%, children 98%), negative predictive value of 99.3% (adults 99.2%, children 100%), and accuracy of 98.5% (adults 98.3%, children 99.2%). When compared with MOG-Ab testing alone, a difference was seen only in adults: a significantly higher specificity (98.9% vs 95.6%, p = 0.0005) and nonstatistically significant lower sensitivity (91.9% vs 100%, p = 0.08). DiscussionThe international MOGAD diagnostic criteria exhibit high performance in selected patients with inflammatory demyelinating diseases (who had a high pretest probability of having

show abstract

The magnetic resonance imaging (MRI) features of intracranial lesions in myelin oligodendrocyte glycoprotein-immunoglobulin G–associated disease (MOGAD)

Wang,

Fang,

Wang

et al. 2025

Clinical Radiology

View full text Add to dashboard Cite

Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS

Cited by 7 publications

References 21 publications

Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody–Associated Disease

Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody–Associated Disease

Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children

The magnetic resonance imaging (MRI) features of intracranial lesions in myelin oligodendrocyte glycoprotein-immunoglobulin G–associated disease (MOGAD)

Contact Info

Product

Resources

About